Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 334Carcinoma, Non-Small-Cell Lung 262Ovarian Neoplasms 177Lung Neoplasms 129Neoplasms 92Fallopian Tube Neoplasms 77Carcinoma, Ovarian Epithelial 63Neoplasm Metastasis 59Esophageal Neoplasms 58Stomach Neoplasms 49Head and Neck Neoplasms 45Squamous Cell Carcinoma of Head and Neck 44Triple Negative Breast Neoplasms 40Endometrial Neoplasms 37Adenocarcinoma of Lung 32Urinary Bladder Neoplasms 28Esophageal Squamous Cell Carcinoma 26Unspecified Adult Solid Tumor, Protocol Specific 24Uterine Cervical Neoplasms 23Carcinoma 23Melanoma 22Breast Neoplasms, Male 22Small Cell Lung Carcinoma 20Prostatic Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 20Adenocarcinoma Of Esophagus 20Recurrence 19Brenner Tumor 18Adenocarcinoma, Bronchiolo-Alveolar 18Peritoneal Neoplasms 16

Interventions

adavosertib 1Paclitaxel 1Gemcitabine 1Carboplatin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation × Paclitaxel × Clear all
NCT02272790 2023-10-03

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AstraZeneca

Phase 2 Completed
95 enrolled 61 charts
Gynecologic

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡